A groundbreaking study led by researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and the Broad Institute of MIT and Harvard has uncovered critical insights into the biology of embryonal tumor with multilayered rosettes (ETMR), a rare and aggressive brain tumor affecting young children. 

Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified adenocarcinoma-like driver mutations in LSCC using next-generation sequencing (NGS), the disease is challenging to treat due to the limited number of detectable mutations for targeted drug therapy. This study aimed to evaluate the mutation profiles of LSCC detected by NGS to assess the relationships between different driver mutations and clinicopathological parameters.

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In colon cancer, the second most common cause of cancer death, such mutations severely limit therapeutic options. The results of a study led by the Center for Cancer Research at the Medical University of Vienna, recently published in the journal EMBO Molecular Medicine, now raise a previously little-considered strategy: the targeted blockade of the EGFR signaling pathway – even in the presence of a KRAS mutation. This could make KRAS-mutated colon cancer more treatable than previously thought.

A case in which a sperm donor was later found to be carrying a cancer-causing pathogenic variant in his gametes has highlighted the lack of cross-border regulation in Europe, which can result in the multiple use of gametes in  families and risks inbreeding and the abnormal  dissemination of inherited diseases.

Lead author Camilo Faust Akl and senior author Francisco Quintana, PhD, both of the Ann Romney Center of Neurologic Diseases at Brigham and Women’s Hospital, published a paper in Nature, “Glioblastoma-instructed astrocytes suppress tumor-1 specific T-cell immunity

The European Society for Medical Oncology (ESMO) is pleased to announce the publication of the latest version of the scale that measures the clinical benefit of cancer treatments, the ESMO-MCBS (ESMO-Magnitude of Clinical Benefit Scale).